Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2024 Filed May 3, 2024 20:26 UTC |
Upadhyay SuketuDirector
|
GrantCommon Stock | 1,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000133 · wk-form4_1714767971.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,727 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:07 UTC |
SACHS BRUCE IDirector
|
GrantDeferred Stock Units · Derivative | 109.49 | $399.58 | $43,750.01 |
DisclosureSEC source: 0000875320-24-000115 · wk-form4_1713384457.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,853.748 Underlying: Common Stock · 109.49 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 20:02 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 240 | $419.00 | $100,560.00 |
DisclosureSEC source: 0000875320-24-000113 · wk-form4_1712174533.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:02 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 225 | $418.10 | $94,072.50 |
DisclosureSEC source: 0000875320-24-000113 · wk-form4_1712174533.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,740 Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:24 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 4,239 | $425.70 | $1,804,542.30 |
DisclosureSEC source: 0000875320-24-000095 · wk-form4_1709069025.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,813 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:29 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 883 | $425.70 | $375,893.10 |
DisclosureSEC source: 0000875320-24-000097 · wk-form4_1709069345.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,965 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:37 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 5,034 | $425.70 | $2,142,973.80 |
DisclosureSEC source: 0000875320-24-000099 · wk-form4_1709069823.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,691 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:44 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
SaleCommon Stock | 883 | $425.70 | $375,893.10 |
DisclosureSEC source: 0000875320-24-000101 · wk-form4_1709070192.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,972 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:59 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 3,004 | $425.70 | $1,278,802.80 |
DisclosureSEC source: 0000875320-24-000107 · wk-form4_1709071114.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,325 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 22:02 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 354 | $425.70 | $150,697.80 |
DisclosureSEC source: 0000875320-24-000109 · wk-form4_1709071355.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,804 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:24 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 3,970 | $431.79 | $1,714,206.30 |
DisclosureSEC source: 0000875320-24-000095 · wk-form4_1709069025.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,052 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:29 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 828 | $431.79 | $357,522.12 |
DisclosureSEC source: 0000875320-24-000097 · wk-form4_1709069345.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,848 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:37 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 4,714 | $431.79 | $2,035,458.06 |
DisclosureSEC source: 0000875320-24-000099 · wk-form4_1709069823.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,725 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:44 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
Tax withholdingCommon Stock | 1,654 | $431.79 | $714,180.66 |
DisclosureSEC source: 0000875320-24-000101 · wk-form4_1709070192.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,855 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:50 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 3,309 | $431.79 | $1,428,793.11 |
DisclosureSEC source: 0000875320-24-000103 · wk-form4_1709070601.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,939 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:55 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 9,386 | $431.79 | $4,052,780.94 |
DisclosureSEC source: 0000875320-24-000105 · wk-form4_1709070906.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,507 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:59 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Tax withholdingCommon Stock | 2,469 | $431.79 | $1,066,089.51 |
DisclosureSEC source: 0000875320-24-000107 · wk-form4_1709071114.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,329 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:02 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 3,309 | $431.79 | $1,428,793.11 |
DisclosureSEC source: 0000875320-24-000109 · wk-form4_1709071355.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,158 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:08 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 3,309 | $431.79 | $1,428,793.11 |
DisclosureSEC source: 0000875320-24-000111 · wk-form4_1709071690.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,583 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:10 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3,002 | $421.77 | $1,266,153.54 |
DisclosureSEC source: 0000875320-24-000085 · wk-form4_1708722602.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,022 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:16 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
SaleCommon Stock | 1,201 | $421.77 | $506,545.77 |
DisclosureSEC source: 0000875320-24-000089 · wk-form4_1708722946.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,509 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:12 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 3,603 | $421.77 | $1,519,637.31 |
DisclosureSEC source: 0000875320-24-000087 · wk-form4_1708722733.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,439 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:20 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 3,191 | $421.77 | $1,345,868.07 |
DisclosureSEC source: 0000875320-24-000091 · wk-form4_1708723213.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,798 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:28 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 360 | $421.77 | $151,837.20 |
DisclosureSEC source: 0000875320-24-000093 · wk-form4_1708723675.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,467 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:13 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 4,002 | $420.79 | $1,684,001.58 |
DisclosureSEC source: 0000875320-24-000066 · wk-form4_1708549975.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,024 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:13 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 2,812 | $420.58 | $1,182,670.96 |
DisclosureSEC source: 0000875320-24-000066 · wk-form4_1708549975.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,026 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:19 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 4,804 | $420.79 | $2,021,475.16 |
DisclosureSEC source: 0000875320-24-000068 · wk-form4_1708550288.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,042 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:19 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 3,373 | $420.58 | $1,418,616.34 |
DisclosureSEC source: 0000875320-24-000068 · wk-form4_1708550288.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,846 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:23 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
SaleCommon Stock | 801 | $420.79 | $337,052.79 |
DisclosureSEC source: 0000875320-24-000070 · wk-form4_1708550607.xml · nonDerivative · entry 3 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,710 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:23 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
Tax withholdingCommon Stock | 1,125 | $420.58 | $473,152.50 |
DisclosureSEC source: 0000875320-24-000070 · wk-form4_1708550607.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,511 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:26 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 2,812 | $420.58 | $1,182,670.96 |
DisclosureSEC source: 0000875320-24-000072 · wk-form4_1708550788.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,248 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:29 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 7,019 | $420.58 | $2,952,051.02 |
DisclosureSEC source: 0000875320-24-000074 · wk-form4_1708550975.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,893 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:34 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 4,118 | $420.58 | $1,731,948.44 |
DisclosureSEC source: 0000875320-24-000076 · wk-form4_1708551231.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,778 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:38 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 4,254 | $420.79 | $1,790,040.66 |
DisclosureSEC source: 0000875320-24-000078 · wk-form4_1708551484.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,989 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:38 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Tax withholdingCommon Stock | 2,623 | $420.58 | $1,103,181.34 |
DisclosureSEC source: 0000875320-24-000078 · wk-form4_1708551484.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,243 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:49 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 2,812 | $420.58 | $1,182,670.96 |
DisclosureSEC source: 0000875320-24-000082 · wk-form4_1708552098.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,892 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:43 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 480 | $420.79 | $201,979.20 |
DisclosureSEC source: 0000875320-24-000080 · wk-form4_1708551763.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,827 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:43 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 3,373 | $420.58 | $1,418,616.34 |
DisclosureSEC source: 0000875320-24-000080 · wk-form4_1708551763.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,307 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:13 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 3,750 | $424.01 | $1,590,037.50 |
DisclosureSEC source: 0000875320-24-000066 · wk-form4_1708549975.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,838 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:19 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 4,499 | $424.01 | $1,907,620.99 |
DisclosureSEC source: 0000875320-24-000068 · wk-form4_1708550288.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,219 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:23 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
Tax withholdingCommon Stock | 1,501 | $424.01 | $636,439.01 |
DisclosureSEC source: 0000875320-24-000070 · wk-form4_1708550607.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,636 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:26 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 3,750 | $424.01 | $1,590,037.50 |
DisclosureSEC source: 0000875320-24-000072 · wk-form4_1708550788.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,060 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:29 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 9,359 | $424.01 | $3,968,309.59 |
DisclosureSEC source: 0000875320-24-000074 · wk-form4_1708550975.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,912 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:38 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Tax withholdingCommon Stock | 3,498 | $424.01 | $1,483,186.98 |
DisclosureSEC source: 0000875320-24-000078 · wk-form4_1708551484.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,866 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:49 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 3,750 | $424.01 | $1,590,037.50 |
DisclosureSEC source: 0000875320-24-000082 · wk-form4_1708552098.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,704 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:43 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 4,499 | $424.01 | $1,907,620.99 |
DisclosureSEC source: 0000875320-24-000080 · wk-form4_1708551763.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,680 Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:07 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 4,655 | $419.16 | $1,951,189.80 |
DisclosureSEC source: 0000875320-24-000064 · wk-form4_1708117602.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,896 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:07 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 4,356 | $419.04 | $1,825,338.24 |
DisclosureSEC source: 0000875320-24-000064 · wk-form4_1708117602.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,551 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $419.04 (range $419.00 to $419.38). Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 21:04 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 737 | $419.13 | $308,898.81 |
DisclosureSEC source: 0000875320-24-000059 · wk-form4_1707944646.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,907 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $419.13 (range $419.00 to $419.37). Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:48 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 1,374 | $420.24 | $577,409.76 |
DisclosureSEC source: 0000875320-24-000041 · wk-form4_1707860917.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,676 F1 · kind: Transaction made pursuant to Ms.Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.